Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 11/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | MAOB | P27338 | 1/20 | 0.52 |
| ▸ | BMP4 | P12644 | 5/20 | 0.52 |
| ▸ | BMPR1B | O00238 | 2/20 | 0.52 |
| ▸ | BMPR1A | P36894 | 2/20 | 0.52 |
| ▸ | ACVRL1 | P37023 | 2/20 | 0.52 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.52 |
| ▸ | ACVR1B | P36896 | 1/20 | 0.52 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.52 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.52 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.52 |
| ▸ | GAK | O14976 | 1/20 | 0.51 |
| ▸ | FLT1 | P17948 | 2/20 | 0.50 |
| ▸ | FLT4 | P35916 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4160576 | 0.80 | KDR (0.52) | KDRKMT2A | |
| SCHEMBL4757135 | 0.75 | KDR (0.68) | KDRKMT2AMAOBBMP4BMPR1B | |
| SCHEMBL27649615 | 0.75 | KDM1A (0.46) | KMT2AMAOB | |
| SCHEMBL7610618 | 0.70 | KDR (1.00) | KDRKMT2ABMP4BMPR1BBMPR1A | |
| SCHEMBL4475017 | 0.69 | KDR (0.61) | KDRKMT2AMAOBBMP4BMPR1B | |
| SCHEMBL11953447 | 0.68 | BMP4 (1.00) | KDRBMP4BMPR1BBMPR1AACVRL1 | |
| SCHEMBL4171150 | 0.68 | KDR (0.66) | KDRKMT2ABMP4FLT1FLT4 | |
| SCHEMBL29395473 | 0.67 | ACVR1 (1.00) | KDRBMP4BMPR1BBMPR1AACVRL1 | |
| SCHEMBL11953869 | 0.67 | ACVR1 (1.00) | KDRBMP4BMPR1BBMPR1AACVRL1 | |
| SCHEMBL2590879 | 0.67 | CYP1A2 (0.48) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1993552-A2 | USE OF PYRAZOLO[1,5A]PYRIMIDIN-7-YL AMINE DERIVATIVES IN THE TREATMENT OF NEUROLOGICAL DISORDERS | Novartis AG (CH) | 2008-11-26 | — | — | EP | disclosed |
| WO-2007103432-A9 | USE OF PYRAZOLO[1,5A]PYRIMIDIN-7-YL AMINE DERIVATIVES IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2008-01-10 | — | — | WO | disclosed |
| WO-2007103432-A2 | USE OF PYRAZOLO[1,5A]PYRIMIDIN-7-YL AMINE DERIVATIVES IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2007-09-13 | — | — | WO | disclosed |